Clinical Response of Tedizolid versus Linezolid in Acute Bacterial Skin and Skin Structure Infections by Severity Measure Using a Pooled Analysis from Two Phase 3 Double-Blind Trials

Abstract

Tedizolid phosphate is approved for the treatment of acute bacterial skin and skin structure infections (ABSSSI). In a pooled analysis of 1,333 ABSSSI patients from the ESTABLISH clinical trials, treatment with tedizolid or linezolid demonstrated similar early and posttherapy clinical responses in nonsevere and severe disease, irrespective of the parameters used to measure ABSSSI severity. Shorter 6-day treatment of ABSSSI, including those that were severe, with tedizolid phosphate demonstrated efficacy comparable to that of 10-day treatment with linezolid. (The ESTABLISH studies discussed in this paper have been registered at ClinicalTrials.gov under identifiers NCT01170221 and NCT01421511.).

Keywords: ABSSSI; clinical response; linezolid; severity; tedizolid phosphate.

Copyright © 2017 American Society for Microbiology.

Figures

FIG 1

(A) Early clinical response (reduction in lesion area of ≥20%) at 42 to 72 h by severity measure. Difference is the weight treatment difference (weighted by study), and the CI was adjusted for the study. (B) Investigator-assessed clinical response at the posttherapy evaluation by severity measures. Difference is the weight treatment difference (weighted by study), and the CI was adjusted for the study. FRS, Faces Rating Scale; LZD, linezolid; TZD, tedizolid; VAS, visual analog scale.